|Slideshows|July 7, 2017

8 Core Principles When Treating Addiction in Adolescents

Author(s)Christopher J. Hammond, MD, PhD, Pravesh Sharma, MD

The main goal in treating addiction is to help the patient achieve and improve functioning. When that patient is also an adolescent, there are special considerations. Here's a quick primer.

Â View the slides in PDF format.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Psyched Perspectives: Substance Use Awareness, A Conversation on Advocacy & Intervention

ByFrank A. Clark, MD,Chelby Drafts

July 31st 2026

Virtual Gambling Disorder Treatment Shows Rapid Symptom Improvement in New Study

ByPatrick Campbell

July 31st 2026

Attachment-Based Therapy in Adolescent Substance Users: A Meta-Synthesis of Emotional Isolation and Avoidant Attachment Patterns

ByBahareh Mahooti

July 28th 2026

Podcast: Managing Co-Occurring Mood and Substance Use Disorders With Michael J. Ostacher, MD, MPH

ByJoseph F. Goldberg, MD,Michael J. Ostacher, MD, MPH

July 17th 2026

Developments in Cannabis Withdrawal and Addiction Treatment

ByGinger Constantine, MD

July 8th 2026

Latest CME

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

In-Person Event

Jersey City Psychiatry

October 2-3, 2026

Register now!

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Video

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

8 Core Principles When Treating Addiction in Adolescents

Related Content

Psyched Perspectives: Substance Use Awareness, A Conversation on Advocacy & Intervention

Virtual Gambling Disorder Treatment Shows Rapid Symptom Improvement in New Study

Attachment-Based Therapy in Adolescent Substance Users: A Meta-Synthesis of Emotional Isolation and Avoidant Attachment Patterns

Podcast: Managing Co-Occurring Mood and Substance Use Disorders With Michael J. Ostacher, MD, MPH

Developments in Cannabis Withdrawal and Addiction Treatment

Latest CME

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jersey City Psychiatry

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Postpartum Psychosis on Trial: What the Lindsay Clancy Case Can Teach Us

FDA Approves Oveporexton for Narcolepsy Type 1, First Drug to Treat Full Range of NT1 Symptoms

Xanomeline/Trospium in Treatment-Refractory Bipolar I Disorder With Psychosis: A Case Report of Rapid Agitation Control and Functional Improvement

Centanafadine in ADHD: Clinical Significance of the First Triple Reuptake Inhibitor for ADHD

Presenting Our August 2026 Theme: Suicide